Thrivent Financial For Lutherans increased its position in Cambrex Corporation (NYSE:CBM) by 7.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,640 shares of the biotechnology company’s stock after acquiring an additional 1,370 shares during the quarter. Thrivent Financial For Lutherans owned about 0.06% of Cambrex Corporation worth $1,173,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CBM. BlackRock Inc. increased its holdings in Cambrex Corporation by 156,940.2% in the 1st quarter. BlackRock Inc. now owns 4,002,955 shares of the biotechnology company’s stock worth $220,363,000 after acquiring an additional 4,000,406 shares in the last quarter. FMR LLC increased its holdings in Cambrex Corporation by 78.2% in the 1st quarter. FMR LLC now owns 899,086 shares of the biotechnology company’s stock worth $49,494,000 after acquiring an additional 394,638 shares in the last quarter. Marshall Wace North America L.P. increased its holdings in Cambrex Corporation by 2,239.4% in the 2nd quarter. Marshall Wace North America L.P. now owns 266,106 shares of the biotechnology company’s stock worth $15,966,000 after acquiring an additional 254,731 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Cambrex Corporation by 34.8% in the 1st quarter. Clearbridge Investments LLC now owns 971,174 shares of the biotechnology company’s stock worth $53,463,000 after acquiring an additional 250,662 shares in the last quarter. Finally, OppenheimerFunds Inc. increased its holdings in Cambrex Corporation by 4,081.5% in the 1st quarter. OppenheimerFunds Inc. now owns 224,798 shares of the biotechnology company’s stock worth $12,375,000 after acquiring an additional 219,422 shares in the last quarter. 98.28% of the stock is owned by institutional investors.

In other news, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total transaction of $736,680.00. Following the completion of the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $5,852,185.92. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total value of $219,840.00. Following the transaction, the chief executive officer now directly owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The disclosure for this sale can be found here. Insiders sold 28,000 shares of company stock valued at $1,574,880 over the last three months. 2.48% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Thrivent Financial For Lutherans Has $1.17 Million Position in Cambrex Corporation (CBM)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/thrivent-financial-for-lutherans-has-1-17-million-position-in-cambrex-corporation-cbm/1611973.html.

Shares of Cambrex Corporation (NYSE:CBM) opened at 56.00 on Friday. The company has a 50-day moving average of $52.67 and a 200 day moving average of $55.32. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 20.40 and a beta of 2.28. Cambrex Corporation has a 12-month low of $38.30 and a 12-month high of $62.95.

Cambrex Corporation (NYSE:CBM) last announced its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same period in the previous year, the company posted $0.68 earnings per share. Cambrex Corporation’s revenue for the quarter was up 13.4% on a year-over-year basis. Analysts predict that Cambrex Corporation will post $3.08 earnings per share for the current year.

Several research firms recently issued reports on CBM. BidaskClub lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. ValuEngine raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. Finally, Zacks Investment Research lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $65.67.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.